Evidence map›Paper›PMID 41365532›Full record

ArticleJournal for immunotherapy of cancer2025

Arecoline upregulates CD155 expression to facilitate immune evasion in oral squamous cell carcinoma.

Qian Wang, Yi Meng, Yuhang Liu, Shanshan Zhang, Yian Wang, Pan Chen, Bo Xiang, Ming Zhou, Zhaojian Gong, Zhaoyang Zeng and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal for immunotherapy of cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Qian Wang *NHC Key Laboratory of Carcinogenesis and Hunan Key Laboratory of Cancer Metabolism, Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, China.
Yi Meng *NHC Key Laboratory of Carcinogenesis and Hunan Key Laboratory of Cancer Metabolism, Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, China.
Yuhang Liu *NHC Key Laboratory of Carcinogenesis and Hunan Key Laboratory of Cancer Metabolism, Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, China.
Shanshan ZhangDepartment of Oral Medicine, Center of Stomatology, Xiangya Hospital Central South University, Changsha, Hunan, China.
Yian WangKey Laboratory of Carcinogenesis and Cancer Invasion of the Chinese Ministry of Education, Cancer Research Institute and Xiangya School of Basic Medicine Sciences, Central South University, Changsha, Hunan, China.
Pan ChenNHC Key Laboratory of Carcinogenesis and Hunan Key Laboratory of Cancer Metabolism, Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, China.
Bo XiangKey Laboratory of Carcinogenesis and Cancer Invasion of the Chinese Ministry of Education, Cancer Research Institute and Xiangya School of Basic Medicine Sciences, Central South University, Changsha, Hunan, China.ORCID http://orcid.org/0000-0003-2641-5434
Ming ZhouKey Laboratory of Carcinogenesis and Cancer Invasion of the Chinese Ministry of Education, Cancer Research Institute and Xiangya School of Basic Medicine Sciences, Central South University, Changsha, Hunan, China.
Zhaojian GongDepartment of Oral and Maxillofacial Surgery, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China xiongwei@csu.edu.cn gongzhaojian4458@csu.edu.cn zengzhaoyang@csu.edu.cn gejunshang@csu.edu.cn.
Zhaoyang ZengNHC Key Laboratory of Carcinogenesis and Hunan Key Laboratory of Cancer Metabolism, Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, China xiongwei@csu.edu.cn gongzhaojian4458@csu.edu.cn zengzhaoyang@csu.edu.cn gejunshang@csu.edu.cn.
Junshang GeKey Laboratory of Carcinogenesis and Cancer Invasion of the Chinese Ministry of Education, Cancer Research Institute and Xiangya School of Basic Medicine Sciences, Central South University, Changsha, Hunan, China xiongwei@csu.edu.cn gongzhaojian4458@csu.edu.cn zengzhaoyang@csu.edu.cn gejunshang@csu.edu.cn.
Wei XiongNHC Key Laboratory of Carcinogenesis and Hunan Key Laboratory of Cancer Metabolism, Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, China xiongwei@csu.edu.cn gongzhaojian4458@csu.edu.cn zengzhaoyang@csu.edu.cn gejunshang@csu.edu.cn.ORCID http://orcid.org/0000-0003-1635-8173

Funding

FACTORS THAT MODIFY INSULIN ACTIONR01DK002001 · NIDDK · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI BUSE, MARIA G · 1986 to 2012
$3.1M
Factors that modify insulin actionR56DK002001 · NIDDK · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI BUSE, MARIA G · 2008 to 2008
$199k
NIDDK NIH HHS R01 DK002001NIDDK NIH HHS R56 DK002001
6 · The paper itself

Abstract

backgroundAreca nut is the fourth most addictive substance worldwide and is a known Group 1 carcinogen. Chronic areca nut chewing has been strongly associated with the development of oral squamous cell carcinoma (OSCC), although the underlying carcinogenic mechanisms remain unclear.

methodsEmploying spatial multiomics technology, we recently mapped the immune microenvironment of areca nut-associated OSCC and identified a marked upregulation of the immune checkpoint molecule CD155 in these tumors. Further quantitative reverse transcription-PCR, western blotting, immunofluorescence, animal experiments, etc, explored and verified the reasons for the upregulation of CD155 caused by arecoline and the results of immune escape in OSCC.

resultsThe investigation revealed that arecoline, a bioactive component of areca nut, induces CD155 expression in OSCC cells. Through interaction with its receptor, TIGIT, CD155 suppresses CD8

conclusionThis study unveils a novel mechanism by which arecoline promotes immune evasion in OSCC and highlights promising immune therapeutic targets and strategies for the treatment of areca nut-associated OSCC.

Indexed as

ArecolineCarcinoma, Squamous CellImmune EvasionMouth NeoplasmsReceptors, VirusSquamous Cell Carcinoma of Head and NeckAnimalsCell Line, TumorGene Expression Regulation, NeoplasticHumansMiceUp-RegulationArecolinepoliovirus receptorReceptors, VirusHead and Neck CancerImmunosuppressionTumor microenvironment - TME

Identifiers

PMID41365532
PMCPMC12699678

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.